MAPT and Alzheimer disease: Determining amyloid β, total Tau, and phosphorylated Tau-181 in CSF samples has emerged as a powerful tool for AD discrimination due to its stability, sensitivity, and specificity (Mielke et al., 2018;Song et al., 2018;Janelidze et al., 2020).